Stock Events

Stock Events

Vertex Pharmaceuticals 

$513.16
1219
+$7.41+1.47% 14:42 Today

Statistics

Day High
513.35
Day Low
502.53
52W High
529.65
52W Low
376.62
Volume
157,197
Avg. Volume
1,568,306
Mkt Cap
130.07B
P/E Ratio
28.82
Dividend Yield
-
Dividend
-

Upcoming

Earnings

9NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
4.06
4.41
4.76
5.11
Expected EPS
4.795103
Actual EPS
N/A

Financials

32.94%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
12BRevenue
3.95BNet Income

Analyst Ratings

565.06Average Price Target
The highest estimate is 641.00.
From 16 ratings within the last 6 months. This is not an investment recommendation.
Buy
88%
Hold
6%
Sell
6%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VRTX. It's not an investment recommendation.
Microsoft
333
MSFT
NVIDIA
318
NVDA
Amazon
297
AMZN
Apple
273
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences competes in the antiviral drug market, similar to Vertex's focus on cystic fibrosis and other diseases.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie competes in the biopharmaceutical field, focusing on treatments for conditions like cystic fibrosis, where Vertex has significant investments.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals is involved in biopharmaceuticals, competing in areas of genetic disorders and diseases, overlapping with Vertex's market.
AMGEN
AMGN
Mkt Cap224.63B
Amgen competes in the biotech sector, focusing on innovative therapies that could rival Vertex's treatments for genetic diseases.
Biogen
BIIB
Mkt Cap31B
Biogen competes in the biotechnology and pharmaceuticals sector, focusing on neurological diseases, a potential competition area for Vertex.
Merck
MRK
Mkt Cap335.14B
Merck & Co. competes across a broad range of therapeutic areas, including those where Vertex is seeking to expand its portfolio.
Pfizer
PFE
Mkt Cap152.69B
Pfizer competes in various therapeutic areas, including genetic disorders, posing competition to Vertex's niche markets.
Novartis
NVS
Mkt Cap286.78B
Novartis competes in multiple segments including treatments for genetic diseases, directly competing with Vertex's portfolio.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca competes in various therapeutic areas, including respiratory diseases, which could overlap with Vertex's cystic fibrosis treatments.

About

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Show more...
CEO
Reshma Kewalramani
Employees
6400
Country
United States
ISIN
US92532F1003
WKN
000882807

Listings

BA
AR
VRTX.BA
XNAS
US
VRTX
STU
DE
VX1.STU
LSE
GB
0QZU.LSE

0 Comments

Share your thoughts

FAQ

What is Vertex Pharmaceuticals stock price today?▼
The current price of VRTX is $513.16 USD — it has increased by +1.47% in the past 24 hours. Watch Vertex Pharmaceuticals stock price performance more closely on the chart.
What is Vertex Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Vertex Pharmaceuticals stocks are traded under the ticker VRTX.
Is Vertex Pharmaceuticals stock price growing?▼
VRTX stock has fallen by -2.05% compared to the previous week, the month change is a +5.66% rise, over the last year Vertex Pharmaceuticals has showed a +30.64% increase.
What is Vertex Pharmaceuticals market cap?▼
Today Vertex Pharmaceuticals has the market capitalization of 130.07B
When is the next Vertex Pharmaceuticals earnings date?▼
Vertex Pharmaceuticals is going to release the next earnings report on November 09, 2026.
What were Vertex Pharmaceuticals earnings last quarter?▼
VRTX earnings for the last quarter are 4.73 USD per share, whereas the estimation was 4.74 USD resulting in a -0.23% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Vertex Pharmaceuticals revenue for the last year?▼
Vertex Pharmaceuticals revenue for the last year amounts to 12B USD.
What is Vertex Pharmaceuticals net income for the last year?▼
VRTX net income for the last year is 3.95B USD.
How many employees does Vertex Pharmaceuticals have?▼
As of August 17, 2026, the company has 6,400 employees.
In which sector is Vertex Pharmaceuticals located?▼
Vertex Pharmaceuticals operates in the Health & Wellness sector.
When did Vertex Pharmaceuticals complete a stock split?▼
The last stock split for Vertex Pharmaceuticals was on August 24, 2000 with a ratio of 2:1.
Where is Vertex Pharmaceuticals headquartered?▼
Vertex Pharmaceuticals is headquartered in BOSTON, United States.